Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q3 2024 · 10-Q
Revenue$167.82M$167.82M+10.4% vs Q3 2023 Net Income-$17.70M-$17.70MN/M vs Q3 2023 EPS Diluted-$0.14-$0.14N/M vs Q3 2023 Gross Profit$74,880,000+20.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flowderived$9,246,000N/M Free Cash Flowderived-$1,553,000N/M Margins · derivedGross margin44.6%+3.6 pt vs Q3 2023
Operating margin-12.6%+3.3 pt vs Q3 2023
Net margin-10.5%+1.6 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 5, 2024 · 36 d after period end